Wells Fargo & Company Boosts CONMED (NYSE:CNMD) Price Target to $42.00

CONMED (NYSE:CNMD) had its price target upped by equities research analysts at Wells Fargo & Company from $41.00 to $42.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 9.66% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Piper Sandler lowered their target price on CONMED from $68.00 to $55.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Bank of America cut their price objective on CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Zacks Research cut shares of CONMED from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 1st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CONMED in a report on Wednesday, January 21st. Finally, Needham & Company LLC reissued a “hold” rating on shares of CONMED in a research note on Thursday. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $52.83.

CONMED Trading Up 2.7%

CONMED stock opened at $38.30 on Thursday. CONMED has a 52-week low of $35.37 and a 52-week high of $74.70. The company has a market cap of $1.19 billion, a P/E ratio of 25.36, a P/E/G ratio of 1.66 and a beta of 0.96. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. The business has a 50-day simple moving average of $41.33 and a two-hundred day simple moving average of $46.35.

CONMED (NYSE:CNMD) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.11. The firm had revenue of $373.20 million for the quarter, compared to analysts’ expectations of $366.88 million. CONMED had a net margin of 3.42% and a return on equity of 14.36%. The business’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.34 EPS. Analysts predict that CONMED will post 4.35 EPS for the current year.

Hedge Funds Weigh In On CONMED

Several hedge funds have recently modified their holdings of the stock. Kelleher Financial Advisors purchased a new position in CONMED during the third quarter valued at $28,000. CWM LLC lifted its stake in CONMED by 352.0% in the 2nd quarter. CWM LLC now owns 791 shares of the company’s stock worth $41,000 after purchasing an additional 616 shares in the last quarter. Quarry LP boosted its holdings in shares of CONMED by 244.8% during the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after purchasing an additional 617 shares during the last quarter. Huntington National Bank grew its position in shares of CONMED by 111.8% during the third quarter. Huntington National Bank now owns 883 shares of the company’s stock valued at $42,000 after purchasing an additional 466 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of CONMED in the second quarter worth about $48,000.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 results beat analysts: CONMED reported $1.43 EPS (vs. $1.32 est.) and $373.2M revenue (vs. $366.9M est.), with revenue up ~7.9% year-over-year — this is the primary catalyst cited for the stock lift. Conmed: Q4 Earnings Snapshot
• Positive Sentiment: Gross-margin and surgical/orthopedic strength highlighted: coverage notes improved gross margin and outperformance in ortho/surgical segments drove the beat and underpin management’s 2026 outlook. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analyst note: Wells Fargo nudged its price target up to $42 (equal-weight), signaling modest upside from current levels and validating the quarter’s credibility. Benzinga
• Positive Sentiment: Management commentary and outlook: call highlights and deep-dive pieces emphasize strategic refocusing and ortho momentum setting the tone for 2026 expectations. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Earnings call transcripts and coverage are widely available for deeper read — useful for investors wanting management detail and segment-level commentary. Earnings Call Transcript
• Neutral Sentiment: Street posture mixed: Needham reaffirmed a Hold rating, indicating some analysts remain cautious despite the beat. Benzinga
• Neutral Sentiment: Analyst models: sell-side consensus still implies moderate 2026 earnings (consensus ~4.35 EPS), so follow-through depends on sustained ortho/surgical momentum and margin trends. Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Technical/valuation headwinds remain: the stock still trades well below its 52‑week high and under longer-term moving averages, so multiple expansion may be limited absent sustained execution.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.